To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
OakLabs GmbH is a privately held company founded in 2011 to deliver most advanced R&D solutions by the combination of highly efficient detection methods with their in-silico modeling processes thus shortening long lasting R&D efforts at materially reduced expenses.Major shareholders are the two founders Martina Schad, Ph.D., and Jim Kallarackal, Ph.D., and the German High-Tech Gründerfonds (HTGF). The founders are experts in molecular biology and quantum physics and act as CEO and Managing Director. OakLabs' team of biologists, chemists, mathematicians, quantum physicists and biostatisticians has extensive experience supporting successful research and discovery projects. OakLabs offers comprehensive services and contract research for industrial and academic research in the fields of biomarker discovery, gene expression analysis, advanced biocomputing, and development of software.
Your Number One Partner in Research and Development
Our core technologies integrate multidisciplinary excellence in: Speciality lab services for gene expression analysis scalable to any type and size of project: Machine learning for the discovery of advanced biomarker signatures for prognostics, diagnostics and prediction. Software development compliant to relevant FDA regulations. Our customers can expect services at predefined costs and fast delivery times due to an efficient integration of biocomputing and superior modeling. We support your Research & Discovery projects with advances solutions for identification of informative biomarkers from any type of molecule using advanced machine learning algorithms. Our outstanding technology for genome-wide and pathway-focussed gene expression analysis provides exceptional data even from single cells and FFPE material. Development & Validation Identification of novel biomarker with enhanced specificity and sensitivity Reduction of sample numbers associated with tremendous savings due to machine learning algorithms Improved planning security with reliable prediction of sample number Efficient streamlining of the marker set towards required sensitivity and specificity Superior speciality lab services for nucleic acid type biomarkers